Skip to main content
. 2007 Oct 11;117(11):3383–3392. doi: 10.1172/JCI31184

Figure 3. Visualization of clone 4 cells within prostates and tumor growth inhibition after αLAG-3 treatment.

Figure 3

We transferred 106 Thy1.1+ clone 4 CD8+ cells into 12- to 15-week-old Thy1.2+ ProHA × TRAMP mice. Mice received VV-HA with or without αLAG-3 on the same day as the cell transfers. Mice receiving αLAG-3 were reinjected with αLAG-3 3 days after transfer. Seven days after cell transfers, mice were sacrificed. Prostates from each group (control, αLAG-3, VV-HA, and VV-HA/αLAG-3) were pooled and subsequently split into 2 groups: one for frozen sections (A and B) and the other for flow cytometry analysis (C). Few prostate-infiltrating lymphocytes were seen in nontreated or αLAG-3–treated mice. H&E and Thy1.1 immunofluorescence revealed lymphocytic infiltration after VV-HA and VV-HA/αLAG-3 treatment with disrupted architecture and Thy1.1 cells invading the prostatic lumen only after VV-HA/αLAG-3 treatment. For Thy1.1 staining, no visible cells were present in control or αLAG-3 samples (data not shown). Original magnification, ×200.